Letter to the Editor: Examining HBV‐RNA Kinetics During NA Treatment—Are NAs Multifunctional Antiviral Agents?
Harel Dahari, Andrew Vaillant, Scott J. Cotler – 13 November 2020
Letter to the Editor: Evaluating Liver Function in Patients With Cirrhosis
Takashi Kokudo – 13 November 2020
Point Shear‐Wave Elastography Using Acoustic Radiation Force Impulse Imaging for the Prediction of Liver‐Related Events in Patients With Chronic Viral Hepatitis
Lisa Hernandez Sampere, Johannes Vermehren, Victoria T. Mücke, Christiana Graf, Kai‐Henrik Peiffer, Georg Dultz, Stefan Zeuzem, Oliver Waidmann, Natalie Filmann, Joerg Bojunga, Christoph Sarrazin, Mireen Friedrich‐Rust, Marcus M. Mücke – 12 November 2020 – Chronic viral hepatitis is associated with substantial morbidity and mortality worldwide.
Doublecortin‐Like Kinase Protein 1 in Cholangiocarcinoma: Is This the Biomarker and Target We Have Been Looking For?
Vik Meadows, Heather Francis – 11 November 2020
MRI‐Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis
Rohit Loomba – 11 November 2020
Hepatic Predictors of Mortality in Severe Acute Respiratory Syndrome Coronavirus 2: Role of Initial Aspartate Aminotransferase/Alanine Aminotransferase and Preexisting Cirrhosis
Shalom Z. Frager, James Szymanski, Jonathan M. Schwartz, Hatef S. Massoumi, Milan Kinkhabwala, Allan W. Wolkoff – 11 November 2020 – The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) is the causative agent of coronavirus disease 2019 (COVID‐19). The presenting symptoms of this virus are variable, and there is an increasing body of literature on risk factors for mortality.
Letter to the Editor: Using Circulating Biomarkers to Stage HCC: Pitfalls and Limitations
Teh‐Ia Huo, Po‐Hong Liu, Chia‐Yang Hsu – 10 November 2020
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
Rohit Loomba, Mazen Noureddin, Kris V. Kowdley, Anita Kohli, Aasim Sheikh, Guy Neff, Bal Raj Bhandari, Nadege Gunn, Stephen H. Caldwell, Zachary Goodman, Ilan Wapinski, Murray Resnick, Andrew H. Beck, Dora Ding, Catherine Jia, Jen‐Chieh Chuang, Ryan S. Huss, Chuhan Chung, G. Mani Subramanian, Robert P. Myers, Keyur Patel, Brian B. Borg, Reem Ghalib, Heidi Kabler, John Poulos, Ziad Younes, Magdy Elkhashab, Tarek Hassanein, Rajalakshmi Iyer, Peter Ruane, Mitchell L. Shiffman, Simone Strasser, Vincent Wai‐Sun Wong, Naim Alkhouri, ATLAS Investigators – 10 November 2020
Innovations in Hepatitis C Screening and Treatment
Arpan A. Patel, Aileen Bui, Eian Prohl, Debika Bhattacharya, Su Wang, Andrea D. Branch, Ponni V. Perumalswami – 10 November 2020 – New therapies offer hope for a cure to millions of persons living with hepatitis C virus (HCV) infection. HCV elimination is a global goal that will be difficult to achieve using the traditional paradigms of diagnosis and care. The current standard has evolved toward universal HCV screening and treatment, to achieve elimination goals. There are several steps between HCV diagnosis and cure with major barriers along the way.
REPLY:
Jeffrey S. Morris, Manal Hassan, Hesham Amin, Ahmed Kaseb – 10 November 2020